Dyadic International (NASDAQ:DYAI) Issues Quarterly Earnings Results

Dyadic International (NASDAQ:DYAI) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02), FiscalAI reports. The business had revenue of $0.96 million during the quarter, compared to analyst estimates of $1.02 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.

Dyadic International Stock Down 14.4%

Shares of NASDAQ:DYAI traded down $0.15 during trading hours on Wednesday, reaching $0.90. The stock had a trading volume of 332,352 shares, compared to its average volume of 180,259. Dyadic International has a 1 year low of $0.65 and a 1 year high of $1.60. The firm’s 50 day moving average is $0.96 and its 200-day moving average is $0.86. The stock has a market capitalization of $32.74 million, a price-to-earnings ratio of -3.91 and a beta of 1.12. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42.

Institutional Trading of Dyadic International

A number of hedge funds and other institutional investors have recently bought and sold shares of DYAI. Landscape Capital Management L.L.C. acquired a new stake in Dyadic International during the third quarter worth approximately $190,000. Geode Capital Management LLC boosted its holdings in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares in the last quarter. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Dyadic International presently has an average rating of “Hold” and an average target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.